menu
    • menu
    [{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra to Screen Clinical-Stage Compounds for Activity in COVID-19 Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"ADX-629","moa":"Reactive aldehyde species","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Aldeyra Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Announces Positive Top-Line Phase 1 Clinical Trial Results and Clinical Development Plans for ADX-629","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ADX-629","moa":"Reactive aldehyde species","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aldeyra Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics to Announce Top-Line Data for Systemic RASP Modulator ADX-629 at 2022 Research & Development Day","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"ADX- 629","moa":"RASP","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics\u2019 Investigational RASP Modulator ADX-629 Improved Signs of Intoxication in Alcohol Challenge Phase 2 Clinical Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"ADX-629","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX-629 in Chronic Cough","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"ADX-629","moa":"","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of ADX-629 in Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"ADX-629","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"ADX-629","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aldeyra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for ADX-629

    Menu

    ADX-629

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aldeyra Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Aldeyra Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADX-629

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Sys...

                            Details : ADX-629 is a novel, orally administered RASP (reactive aldehyde species) modulator which is under phase 2 clinical development for the potential treatment of Sjögren-Larsson Syndrome & moderate alcoholic hepatitis.

                            Brand Name : ADX-629

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 04, 2024

                            Lead Product(s) : ADX-629

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aldeyra Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Aldeyra Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADX-629

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aldeyra Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of ADX-629 in Atopic Dermatitis

                            Details : ADX-629 is an investigational new drug, is a novel, orally administered RASP (reactive aldehyde species) modulator for the potential treatment of systemic immune-mediated diseases. It s being devloped for the treament for chronic cough .

                            Brand Name : ADX-629

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 06, 2023

                            Lead Product(s) : ADX-629

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Aldeyra Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Aldeyra Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADX-629

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX-629 in Chronic Cough

                            Details : ADX-629 is an investigational new drug, is a novel, orally administered RASP (reactive aldehyde species) modulator for the potential treatment of systemic immune-mediated diseases. It s being devloped for the treament for chronic cough .

                            Brand Name : ADX-629

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 30, 2023

                            Lead Product(s) : ADX-629

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Aldeyra Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Aldeyra Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADX-629

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aldeyra Therapeutics’ Investigational RASP Modulator ADX-629 Improved Signs of Intoxication in Alcohol Chall...

                            Details : ADX-629 reduced dermal flushing (P=0.0007), increased Romberg test balance time (P=0.02), and lowered levels of the ethanol RASP metabolite acetaldehyde (P=0.03) following acute exposure to alcohol.

                            Brand Name : ADX-629

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 13, 2022

                            Lead Product(s) : ADX-629

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Aldeyra Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Aldeyra Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADX-629

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aldeyra Therapeutics to Announce Top-Line Data for Systemic RASP Modulator ADX-629 at 2022 Research & Developm...

                            Details : Treatment with ADX-629 led to statistically significant reductions in plasma levels of the pro-inflammatory cytokines IL-5 (p=0.02) and TNFα (p<0.0001), and numerical reductions in plasma levels of malondialdehyde.

                            Brand Name : ADX-629

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 29, 2022

                            Lead Product(s) : ADX-629

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Aldeyra Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Aldeyra Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADX-629

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aldeyra Announces Positive Top-Line Phase 1 Clinical Trial Results and Clinical Development Plans for ADX-629

                            Details : ADX-629 was well-tolerated, and no treatment-related adverse events were observed in the trial.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 14, 2020

                            Lead Product(s) : ADX-629

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Aldeyra Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Aldeyra Therapeutics

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ADX-629

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aldeyra to Screen Clinical-Stage Compounds for Activity in COVID-19 Infection

                            Details : Aldeyra will begin screening its library of novel reactive aldehyde species inhibitors, including ADX-629 and reproxalap, for potential anti-inflammatory and antiviral activity in COVID-19 infection.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 24, 2020

                            Lead Product(s) : ADX-629

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth